Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

Rau, Daniela; Lang, Michael; Harth, Andreas; Naumann, Markus; Weber, Frank; Tumani, Hayrettin; Bayas, Antonios

doi:10.3390/ijms160714669

Cited by 74 publications

(60 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cases of PML have not been reported thus far in patients with MS, but only in hematological and transplantation indications [71][72][73]. Cases of listeria infections have been reported, some with a severe disease course [74]. Many of the safety issues (especially emergent autoimmune complications) are quite common but appear to follow a known temporal sequence.…”

Section: Alemtuzumabmentioning

confidence: 99%

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

2016

View full text Add to dashboard Cite

Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of diseasemodifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.

show abstract

Section: Alemtuzumabmentioning

confidence: 99%

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

2016

View full text Add to dashboard Cite

show abstract

“…The ability of Alemtuzumab to deplete dendritic cells as well may explain cases of Listeria meningitis linked to the initial Alemtuzumab infusions [9,67,68]. Listeria meningitis infection may be facilitated by immune cell depletion in the adaptive as well as the innate immune system, possibly by an outburst of a pre-existing, clinically silent and CD8+ T cell controlled infection due to cellular depletion and activation blockade.…”

Section: Infectionsmentioning

confidence: 99%

Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

Hassoun

Eisele

Thomas

et al. 2016

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unknown function which is found on B and T lymphocytes, leading to depletion followed by repopulation of these cells. The high efficacy of Alemtuzumab in controlling relapsing remitting MS has been shown in several clinical trials. This new therapy approach is associated with a specific side effects profile requiring regular longterm monitoring. The most important side effects are infusion-associated reactions, a slight increase of infections as well as autoimmune events in almost one third of treated patients. Based on two years of clinical experience in Germany, this review covers the first steps with the careful patient selection to be treated with Alemtuzumab over the preparation steps and the infusion courses up to the longterm monitoring after Alemtuzumab treatment.

show abstract

“…B. eine Tuberkulose, eine Spirochätengingivitis, eine Pasteurellainfektion sowie eine ösophageale Candidiasis [54]. Nach Zulassung wurden einige Fäl-le von Listerienmeningitis bekannt, die kurz nach Infusion auftraten und unter Antibiotikatherapie gut behandelbar waren [70].…”

Section: Alemtuzumab (Lemtrada ® )unclassified

Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

et al. 2016

View full text Add to dashboard Cite

With the approval of various substances for the immunotherapy of multiple sclerosis (MS), treatment possibilities have improved significantly over the last few years. Indeed, the choice of individually tailored preparations and treatment monitoring for the treating doctor is becoming increasingly more complex. This is particularly applicable for monitoring for a treatment-induced compromise of the immune system. The following article by members of the German Multiple Sclerosis Skills Network (KKNMS) and the task force "Provision Structures and Therapeutics" summarizes the practical recommendations for approved immunotherapy for mild to moderate and for (highly) active courses of MS. The focus is on elucidating the substance-specific relevance of particular laboratory parameters with regard to the mechanism of action and the side effects profile. To enable appropriate action to be taken in clinical practice, any blood work changes that can be expected, in addition to any undesirable laboratory findings and their causes and relevance, should be elucidated.

show abstract

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

Cited by 74 publications

References 18 publications

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

Hands on Alemtuzumab-experience from clinical practice: whom and how to treat

Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

Contact Info

Product

Resources

About